FOX Business' Lydia Hu reports on the latest news emerging from the pharmaceutical industry as the U.S.’ medication shortage reaches a new record.

"Something is rotten in the state of Denmark," as Hamlet said in Shakespeare’s time. It was true then, and it’s true today.

While Senate Democrats are holding our government hostage to their ridiculous shutdown so they can provide free healthcare to illegal aliens, federal services are going unfulfilled. One foreign company is trying to exploit this to keep its profits as fat as possible.

Novo Nordisk, a biotech company based in Denmark, is attempting to intervene in the American pharmaceutical market to suppress competition, protect its dominant market position, and stop a weight-loss drug competitor from entering the market.

WEIGHT LOSS COULD BE JUST A PILL AWAY, STUDY OF NEW MEDICATION SUGGESTS

Novo, the maker of Ozempic and Wegovy, has a significant market share in the GLP1 drug space, which has revolutionized the medical treatment of obesity. Given the devastating problems of obesity-related illnesses, this is a huge industry, with the potential for both billions in revenue and the........

© Fox Business